Gérard Hascoët, a veteran entrepreneur, is the new chairman of the Board at EOS imaging. Hascoët succeeds Mike J. Dormer, chairman of the company’s Board since 2012.
Gerard Hascoet Becomes Chairman of the Board at EOS imaging
1 min read Premium comments
“Since 2012, EOS imaging has executed a remarkable growth strategy and I am delighted that an entrepreneur as talented as Gérard Hascoët will now be helping the company continue this development, ” said Mike J. Dormer, in the July 30, 3015 news release.
Roughly 30 years ago, Hascoët began his career at Thomson CGR. In 1985 he founded Technomed International, now within EDAP TMS, a company dedicated to non-invasive medical treatment in urology. In 1993, he founded Sometec, a hemodynamic monitoring company divested to Arrow International, and IMMI, a neurosurgical robotics company divested to ISS. From 2008 to 2011, Hascoët was CEO of SpineVision, a spinal implant company of which he still is Board member. In 2009, he co-founded MD Start, a European incubator for medical technology companies, of which he is currently Executive Chairman. Hascoët is also Venture Partner of Sofinnova.
“Since 2012, EOS imaging has executed a remarkable growth strategy and I am delighted that an entrepreneur as talented as Gérard Hascoët will now be helping the company continue this development, ” Dormer said.
EOS imaging CEO Marie Meynadier added, “We are very happy with our achievements over the last three years and extremely thankful to Mike’s support over that decisive period. Gérard Hascoët’s strategic vision and entrepreneurial expertise in medical devices will be key assets to the company’s progress in establishing a leadership position in orthopedic solutions based on imaging.”
Hascoët told OTW, “I was drawn to EOS imaging due to the company’s strong technology and interest in growing globally as a leader in orthopedic imaging. EOS has seen success in this expansion and I am excited to help guide the company in developing the strategy for continued growth. In working with the large U.S. market, we will be evaluating opportunities to expand the company’s business model to include related recurring revenue. I look forward to utilizing my background in medical device growth companies to help EOS imaging further develop its industry leadership.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.